Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

NewAmsterdam Pharma Company N.V. - Ordinary Shares (NQ: NAMS )

19.93 +0.49 (+2.52%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 140,271
Open 19.21
Bid (Size) 17.77 (5)
Ask (Size) 31.90 (2)
Prev. Close 19.44
Today's Range 19.21 - 20.32
52wk Range 5.633 - 26.35
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease
Enrollment to continue to the end of April to accommodate strong patient and site interest 
From NewAmsterdam Pharma N.V
Via GlobeNewswire
NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer
From NewAmsterdam Pharma N.V
Via GlobeNewswire

Performance

YTD
+66.78%
+66.78%
1 Month
-9.61%
-9.61%
3 Month
+13.24%
+13.24%
6 Month
+165.73%
+165.73%
1 Year
+34.57%
+34.57%

More News

Read More
NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress
From NewAmsterdam Pharma N.V
Via GlobeNewswire
NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVD
From NewAmsterdam Pharma N.V
Via GlobeNewswire
NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update
From NewAmsterdam Pharma N.V
Via GlobeNewswire
NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in March
From NewAmsterdam Pharma N.V
Via GlobeNewswire
NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
From NewAmsterdam Pharma N.V
Via GlobeNewswire
NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
From NewAmsterdam Pharma N.V
Via GlobeNewswire
NewAmsterdam Pharma to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
From NewAmsterdam Pharma N.V
Via GlobeNewswire
World Acceptance Posts Upbeat Earnings, Joins Kaman, Spirit Airlines And Other Big Stocks Moving Higher On Friday
Via Benzinga
Topics Stocks
Exposures US Equities
Why TransCode Therapeutics Shares Are Trading Lower By Over 24%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Cholesterol Player NewAmsterdam Pharma's Obicetrapib Is A Potential Blockbuster In Cardiovascular Market: Bullish Analyst Says
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Why WD-40 Shares Are Trading Higher By Over 17%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
NewAmsterdam Pharma Appoints William H. Lewis, J.D., M.B.A. as Chair of its Board of Directors
From NewAmsterdam Pharma N.V
Via GlobeNewswire
NewAmsterdam Pharma Announces 2024 Strategic Priorities
From NewAmsterdam Pharma N.V
Via GlobeNewswire
NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter 2023 Financial Highlights
From NewAmsterdam Pharma N.V
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
FMC, Li-Cycle Holdings, Okta And Other Big Stocks Moving Lower On Monday
Via Benzinga
Topics Stocks
Exposures US Equities
Why EngageSmart Shares Are Trading Higher By Around 12%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
NewAmsterdam Pharma Announces Appointment of Ian Somaiya as Chief Financial Officer
From NewAmsterdam Pharma N.V
Via GlobeNewswire
NewAmsterdam Pharma Announces Initial Data from Phase 2a Clinical Trial Evaluating Obicetrapib in Patients with Early Alzheimer’s Disease Who Carry an ApoE4 Mutation
From NewAmsterdam Pharma N.V
Via GlobeNewswire
NewAmsterdam Pharma to Present at 2023 Cantor Fitzgerald Global Healthcare Conference
From NewAmsterdam Pharma N.V
Via GlobeNewswire
NewAmsterdam Pharma Announces Appointment of William “BJ” Jones, formerly of Biohaven Pharmaceuticals, as Chief Commercial Officer
From NewAmsterdam Pharma Company B.V.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.